

Michael Levy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6209442/publications.pdf>

Version: 2024-02-01

180
papers

11,291
citations

50170

46
h-index

30848

102
g-index

184
all docs

184
docs citations

184
times ranked

7789
citing authors

#	ARTICLE	IF	CITATIONS
1	Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2022, 28, 1663-1666.	1.4	9
2	Optic Neuritisâ€“Independent Retinal Atrophy in Neuromyelitis Optica Spectrum Disorder. Journal of Neuro-Ophthalmology, 2022, 42, e40-e47.	0.4	5
3	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Multiple Sclerosis Journal, 2022, 28, 480-486.	1.4	32
4	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology, 2022, 269, 1786-1801.	1.8	8
5	Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies. Multiple Sclerosis and Related Disorders, 2022, 57, 103332.	0.9	7
6	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Multiple Sclerosis and Related Disorders, 2022, 57, 103352.	0.9	19
7	Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Neurology and Therapy, 2022, 11, 123-135.	1.4	21
8	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	0.9	11
9	Implications of Low-Titer MOG Antibodies. Multiple Sclerosis and Related Disorders, 2022, 59, 103746.	0.9	10
10	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. JAMA Neurology, 2022, 79, 518.	4.5	39
11	A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2022, 60, 103716.	0.9	3
12	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€“Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	64
13	Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review. Journal of Neuro-Ophthalmology, 2022, 42, 154-162.	0.4	12
14	Is there a link between neuropathic pain and constipation in NMOSD and MOGAD? Results from an online patient survey and possible clinical implications. Multiple Sclerosis and Related Disorders, 2022, 63, 103825.	0.9	2
15	Eculizumab therapy in a patient with secondary progressive multiple sclerosis. Neuroimmunology Reports, 2022, 2, 100111.	0.2	2
16	A Response to: Letter to the Editor Regarding â€œNetwork Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorderâ€œ. Neurology and Therapy, 2022, 11, 1445-1449.	1.4	2
17	Treatment outcomes of first-ever episode of severe optic neuritis. Multiple Sclerosis and Related Disorders, 2022, 66, 104020.	0.9	3
18	Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD. Multiple Sclerosis Journal, 2021, 27, 1738-1748.	1.4	19

#	ARTICLE	IF	CITATIONS
19	New therapies for neuromyelitis optica spectrum disorder. <i>Lancet Neurology</i> , The, 2021, 20, 60-67.	4.9	86
20	Is multiple sclerosis overdiagnosed?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102721.	0.9	2
21	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102641.	0.9	26
22	Air pollution and multiple sclerosis risk. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102797.	0.9	3
23	Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. <i>Annals of Neurology</i> , 2021, 89, 1088-1098.	2.8	55
24	B cell therapy and the use of RNA-based COVID-19 vaccines. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102887.	0.9	5
25	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102931.	0.9	2
26	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102849.	0.9	7
27	Editorial: Epidemiology of Atypical Demyelinating Diseases. <i>Frontiers in Neurology</i> , 2021, 12, 662353.	1.1	2
28	Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice. <i>Neurology and Therapy</i> , 2021, 10, 767-783.	1.4	22
29	Should Immunosuppressive Therapy Be Modified During a Pandemic?. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, 266-271.	0.4	0
30	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103155.	0.9	12
31	B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 325-331.	2.7	5
32	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	0.9	7
33	Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life. <i>Journal of the Neurological Sciences</i> , 2021, 428, 117546.	0.3	6
34	Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103189.	0.9	37
35	Evidence for and against subclinical disease activity and progressive disease in MOC antibody disease and neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2021, 360, 577702.	1.1	13
36	Differential diagnosis of multiple sclerosis. <i>Presse Medicale</i> , 2021, 50, 104092.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Expanding the spectrum of MOG antibody disease. <i>Multiple Sclerosis Journal</i> , 2020, 26, 515-516.	1.4	6
38	Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1360-1371.	1.4	75
39	Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101920.	0.9	35
40	Cognitive functions in Egyptian neuromyelitis optica spectrum disorder.. <i>Clinical Neurology and Neurosurgery</i> , 2020, 189, 105621.	0.6	8
41	Update on neuromyelitis optica spectrum disorder. <i>Current Opinion in Ophthalmology</i> , 2020, 31, 462-468.	1.3	24
42	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	18.1	232
43	Rodent Models of Optic Neuritis. <i>Frontiers in Neurology</i> , 2020, 11, 580951.	1.1	9
44	“Rocking the boat” with a new drug for neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102458.	0.9	0
45	Paroxysmal symptoms in neuromyelitis optica spectrum disorder: Results from an online patient survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102578.	0.9	4
46	Rethinking high-risk groups in COVID-19. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102139.	0.9	39
47	Scrambler therapy improves pain in neuromyelitis optica. <i>Neurology</i> , 2020, 94, e1900-e1907.	1.5	22
48	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110
49	The COVID-19 pandemic and the use of MS disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 102073.	0.9	153
50	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102027.	0.9	11
51	MRI differences between MOG antibody disease and AQP4 NMOSD. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1854-1865.	1.4	81
52	Ageing and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101953.	0.9	1
53	Interleukin-6 receptor blockade for the treatment of NMOSD. <i>Lancet Neurology</i> , The, 2020, 19, 370-371.	4.9	3
54	Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy. <i>Current Neuropharmacology</i> , 2020, 19, 220-232.	1.4	24

#	ARTICLE	IF	CITATIONS
55	Dare we mention the C-word?. Multiple Sclerosis and Related Disorders, 2020, 43, 102340.	0.9	0
56	Risk of Hematoma From Aspirin or Clopidogrel Owing to Lumbar Puncture. Mayo Clinic Proceedings, 2019, 94, 1552-1555.	1.4	9
57	Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2019, 33, A1-A2.	0.9	8
58	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e583.	3.1	33
59	MRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified Etiology. American Journal of Neuroradiology, 2019, 40, 1427-1432.	1.2	8
60	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
61	Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Multiple Sclerosis and Related Disorders, 2019, 29, 15-22.	0.9	33
62	Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Management Nursing, 2019, 20, 580-591.	0.4	11
63	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain, 2019, 142, 1598-1615.	3.7	62
64	Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 2019, 381, 614-625.	13.9	536
65	One size doesn't fit all. Multiple Sclerosis and Related Disorders, 2019, 31, A1-A2.	0.9	0
66	Three suggestions to decrease the financial burden of MS treatments. Multiple Sclerosis and Related Disorders, 2019, 30, A1.	0.9	0
67	Aquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected Progression. Cancer Investigation, 2019, 37, 67-72.	0.6	4
68	Ten years of iron chelation in a patient with superficial siderosis. Neurological Sciences, 2019, 40, 1947-1949.	0.9	4
69	MOG antibody-associated encephalomyelitis/encephalitis. Multiple Sclerosis Journal, 2019, 25, 1427-1433.	1.4	67
70	Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. American Journal of Neuroradiology, 2019, 40, 726-731.	1.2	8
71	Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease. Multiple Sclerosis and Related Disorders, 2019, 29, A1-A2.	0.9	0
72	Multiple Sclerosis and Vitamin D - Caviar or a Dog's Dinner?. Multiple Sclerosis and Related Disorders, 2019, 28, A1-A2.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 231-235.	0.9	13
74	<i>Reply:</i>. <i>American Journal of Neuroradiology</i> , 2019, 40, E62.	1.2	0
75	A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. <i>Medicine (United States)</i> , 2019, 98, e15944.	0.4	42
76	Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 60-63.	0.9	23
77	Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 64-68.	0.9	44
78	Should our treatment target in MS include the intrathecal plasma cell response?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, A1-A2.	0.9	1
79	Rituximab during pregnancy in neuromyelitis optica: A case report. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e542.	3.1	11
80	Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. <i>International Journal of MS Care</i> , 2019, 21, 129-134.	0.4	29
81	Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis. <i>International Journal of MS Care</i> , 2019, 21, 76-80.	0.4	7
82	Investigational drugs in development to prevent neuromyelitis optica relapses. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 265-271.	1.9	40
83	Familial monophasic acute transverse myelitis due to the pathogenic variant in <i>VPS37A</i>. <i>Neurology: Genetics</i> , 2018, 4, e213.	0.9	4
84	Are the high-costs of MS disease-modifying therapies justified?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, A3-A5.	0.9	2
85	Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. <i>Journal of the Neurological Sciences</i> , 2018, 384, 96-103.	0.3	40
86	Two-€year observational study of deferiprone in superficial siderosis. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 187-192.	1.9	41
87	Editors-™ Welcome. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, A1-A2.	0.9	0
88	Recurrent Dysarthria and Ataxia in a Young Girl. <i>JAMA Neurology</i> , 2018, 75, 125.	4.5	0
89	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1737-1742.	1.4	41
90	Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. <i>Neurology</i> , 2018, 90, e12-e21.	1.5	72

#	ARTICLE	IF	CITATIONS
91	Effect of CXCR2 Inhibition on Behavioral Outcomes and Pathology in Rat Model of Neuromyelitis Optica. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	2
92	2189 Scrambler therapy: Potential new treatment for central neuropathic pain?. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 47-47.	0.3	0
93	Vaccines and disease-modifying treatments. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, A1-A2.	0.9	7
94	Area postrema syndrome. <i>Neurology</i> , 2018, 91, e1642-e1651.	1.5	129
95	Is Corticospinal Tract Degeneration Caused by Sjögren Syndrome?. <i>Journal of Clinical Neurology</i>		

#	ARTICLE	IF	CITATIONS
109	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e339.	3.1	32
110	Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. <i>American Journal of Neuroradiology</i> , 2017, 38, 949-953.	1.2	8
111	Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results. <i>Journal of Neurology</i> , 2017, 264, 2284-2292.	1.8	25
112	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2017, 89, 2238-2244.	1.5	59
113	Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 198-201.	0.9	36
114	Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 116-122.	0.9	43
115	Clinical Reasoning: A patient with a history of encephalomyelitis and recurrent optic neuritis. <i>Neurology</i> , 2017, 89, e231-e234.	1.5	1
116	A Novel GFAP Mutation in Late-Onset Alexander Disease Showing Diffusion Restriction. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
127	Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. <i>Multiple Sclerosis Journal</i> , 2016, 22, 302-311.	1.4	106
128	Regenerative cellular therapies for neurologic diseases. <i>Brain Research</i> , 2016, 1638, 88-96.	1.1	31
129	Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. <i>Multiple Sclerosis Journal</i> , 2016, 22, 185-192.	1.4	185
130	What do we know about brain contrast enhancement patterns in neuromyelitis optica?. <i>Clinical Imaging</i> , 2016, 40, 573-580.	0.8	25
131	The ethics of placebo controlled clinical trials in NMO – A balance of risks. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 512-514.	0.9	5
132	Minimally-invasive Technique for Injection into Rat Optic Nerve. <i>Journal of Visualized Experiments</i> , 2015, , e52249.	0.2	0
133	Bevacizumab is safe in acute relapses of neuromyelitis optica. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 413-418.	0.5	39
134	Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 355, 59-63.	0.3	68
135	Facilitating Early-In-Day Discharge for Multiple Sclerosis Patients Treated With Intravenous Methylprednisolone. <i>Neurohospitalist, The</i> , 2015, 5, 197-204.	0.3	1
136	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	4.5	59
137	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	1.4	209
138	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.5	3,275
139	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815.	1.5	39
140	Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. <i>Acta Neuropathologica Communications</i> , 2015, 3, 28.	2.4	44
141	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	3.1	104
142	Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. <i>Journal of Neuroimmunology</i> , 2015, 287, 29-30.	1.1	7
143	Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 843-847.	1.4	154
144	Immunopathogenesis of Neuromyelitis Optica. <i>Advances in Immunology</i> , 2014, 121, 213-242.	1.1	55

#	ARTICLE	IF	CITATIONS
145	Predictors of recurrence following an initial episode of transverse myelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e4.	3.1	35
146	Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica. <i>JAMA Neurology</i> , 2014, 71, 324.	4.5	258
147	Does Aquaporin-4“Seronegative Neuromyelitis Optica Exist?. <i>JAMA Neurology</i> , 2014, 71, 271.	4.5	4
148	Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e5.	3.1	46
149	Evidence for classic complement activity in neuromyelitis optica. , 2014, 33, 251-252.		7
150	Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. <i>BMC Neurology</i> , 2013, 13, 104.	0.8	23
151	In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. <i>Neurology</i> , 2013, 80, 1406-1414.	1.5	138
152	Auditory Profile in Superficial Siderosis of the Central Nervous System. <i>Otology and Neurotology</i> , 2013, 34, 611-619.	0.7	8
153	What Is the True Clinicopathologic Spectrum of Neuromyelitis Optica?â€”Reply. <i>JAMA Neurology</i> , 2013, 70, 272.	4.5	2
154	The Preoperative Neurological Evaluation. <i>Neurohospitalist</i> , The, 2013, 3, 209-220.	0.3	11
155	Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. <i>Neurology Research International</i> , 2012, 2012, 1-13.	0.5	64
156	Diagnosing CNS Vasculitis. <i>Neurologist</i> , 2012, 18, 233-238.	0.4	19
157	Use of MR Cell Tracking to Evaluate Targeting of Glial Precursor Cells to Inflammatory Tissue by Exploiting the Very Late Antigen-4 Docking Receptor. <i>Radiology</i> , 2012, 265, 175-185.	3.6	52
158	Pilot Safety Trial of Deferiprone in 10 Subjects With Superficial Siderosis. <i>Stroke</i> , 2012, 43, 120-124.	1.0	54
159	Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease. <i>Archives of Neurology</i> , 2012, 69, 352.	4.9	21
160	Noninvasive Monitoring of Immunosuppressive Drug Efficacy to Prevent Rejection of Intracerebral Glial Precursor Allografts. <i>Cell Transplantation</i> , 2012, 21, 2149-2157.	1.2	15
161	Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. <i>Brain</i> , 2012, 135, 521-533.	3.7	306
162	Epidemiology of Neuromyelitis Optica in the United States. <i>Archives of Neurology</i> , 2012, 69, 1176-80.	4.9	239

#	ARTICLE	IF	CITATIONS
163	Treatment of neuromyelitis optica: Review and recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 180-187.	0.9	217
164	Review of animal models of neuromyelitis optica. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 174-179.	0.9	16
165	A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. <i>Journal of Neurology</i> , 2012, 259, 801-816.	1.8	49
166	Dry beriberi mimicking Guillain-Barré syndrome as the first presenting sign of thiamine deficiency. <i>European Journal of Neurology</i> , 2012, 19, e14-5.	1.7	16
167	Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic. <i>Journal of the Neurological Sciences</i> , 2011, 306, 24-28.	0.3	48
168	n-Dodecyl- β -D-Maltoside Inhibits Aggregation of Human Interferon- β and Reduces Its Immunogenicity. <i>Journal of Neuroimmune Pharmacology</i> , 2011, 6, 158-162.	2.1	30
169	Deferiprone Reduces Hemosiderin Deposits in the Brain of a Patient with Superficial Siderosis: Fig 1.. <i>American Journal of Neuroradiology</i> , 2011, 32, E1-E2.	1.2	30
170	Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. <i>Journal of Neuroimmunology</i> , 2010, 221, 68-72.	1.1	27
171	Safe and Effective Intravenous Thrombolysis for Acute Ischemic Stroke Caused by Left Atrial Myxoma. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2009, 18, 398-402.	0.7	48
172	Neuromyelitis optica pathogenesis and aquaporin 4. <i>Journal of Neuroinflammation</i> , 2008, 5, 22.	3.1	138
173	Reversible Chest Tube Horner Syndrome. <i>Journal of Neuro-Ophthalmology</i> , 2008, 28, 212-213.	0.4	13
174	Finding NMO. <i>Neurology</i> , 2008, 70, 334-335.	1.5	4
175	Superficial siderosis: a case report and review of the literature. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 54-58.	2.7	152
176	Mitochondrial Regulation of Synaptic Plasticity in the Hippocampus. <i>Journal of Biological Chemistry</i> , 2003, 278, 17727-17734.	1.6	163
177	The Role of Mitochondrial Porins and the Permeability Transition Pore in Learning and Synaptic Plasticity. <i>Journal of Biological Chemistry</i> , 2002, 277, 18891-18897.	1.6	154
178	The Other Half of Hebb. <i>Molecular Neurobiology</i> , 2002, 25, 051-066.	1.9	28
179	Lactase deficiency in Mexican-American males. <i>American Journal of Clinical Nutrition</i> , 1972, 25, 869-870.	2.2	23
180	Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD Within a Real-World Cohort. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	13